BPC-157 is a signaling peptide that upregulates growth factors involved in tissue repair, particularly VEGF (new blood vessel formation), fibroblast activity (collagen production), and nitric oxide signaling
The single human dataset for musculoskeletal use is a retrospective chart review of sixteen knee-pain patients who paid for intra-articular injections, with subjective improvement reported in fourteen and no control, no blinded assessment, and no objective imaging endpoint
A clean Certificate of Analysis from the supplier is not the same as an independent third-party assay, and almost no buyer is in a position to audit the difference
BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans
Long-Term Cardiovascular Considerations Questions about long-term BPC-157 use remain largely unanswered by current research
BPC-157 is also classified by WADA as a prohibited substance for competitive athletes, which is a regulatory consideration separate from safety